DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:067080)
South Korea · Delayed Price · Currency is KRW 13,940
-210 (-1.48%)
At close: Apr 9, 2026
DAE HWA Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 143,060 | 149,409 | 141,359 | 131,912 | 117,159 |
Other Revenue | - | - | -0 | - | - |
| 143,060 | 149,409 | 141,359 | 131,912 | 117,159 | |
Revenue Growth (YoY) | -4.25% | 5.70% | 7.16% | 12.59% | 7.14% |
Cost of Revenue | 96,121 | 97,197 | 96,698 | 86,298 | 73,907 |
Gross Profit | 46,939 | 52,212 | 44,661 | 45,614 | 43,252 |
Selling, General & Admin | 37,203 | 36,677 | 34,309 | 32,496 | 31,345 |
Research & Development | 5,185 | 7,241 | 5,984 | 5,374 | 6,641 |
Amortization of Goodwill & Intangibles | 901.53 | 979.8 | 1,080 | 1,050 | 1,017 |
Other Operating Expenses | 354.85 | 348.08 | 347.44 | 352.59 | 308.25 |
Operating Expenses | 43,777 | 45,500 | 42,699 | 39,767 | 39,968 |
Operating Income | 3,162 | 6,712 | 1,962 | 5,847 | 3,284 |
Interest Expense | -4,794 | -5,458 | -4,674 | -2,365 | -1,519 |
Interest & Investment Income | 125.96 | 30.35 | 341.26 | 348.19 | 427.24 |
Earnings From Equity Investments | - | - | - | - | -212.81 |
Currency Exchange Gain (Loss) | -68.05 | -158.7 | 44.83 | -15.35 | 104.33 |
Other Non Operating Income (Expenses) | 1,623 | 1,091 | 1,661 | 2,253 | 4,019 |
EBT Excluding Unusual Items | 49.94 | 2,217 | -664.3 | 6,067 | 6,103 |
Impairment of Goodwill | - | - | - | - | -1,431 |
Gain (Loss) on Sale of Investments | 181.57 | -366.55 | 381.4 | -766.9 | 362.47 |
Gain (Loss) on Sale of Assets | - | - | -18.07 | -1.21 | -1.07 |
Asset Writedown | 4,547 | -337 | -155 | -2,873 | -1,182 |
Other Unusual Items | - | - | - | 0.05 | 673.21 |
Pretax Income | 4,779 | 1,513 | -455.97 | 2,426 | 4,525 |
Income Tax Expense | 2,449 | 683.33 | 58.35 | 1,205 | 2,562 |
Earnings From Continuing Operations | 2,330 | 829.84 | -514.32 | 1,221 | 1,962 |
Minority Interest in Earnings | -676.46 | -298.42 | -632.48 | -105.5 | 254.96 |
Net Income | 1,654 | 531.42 | -1,147 | 1,116 | 2,217 |
Net Income to Common | 1,654 | 531.42 | -1,147 | 1,116 | 2,217 |
Net Income Growth | 211.15% | - | - | -49.69% | - |
Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 17 |
Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 17 |
Shares Change (YoY) | -0.70% | 1.13% | - | 0.33% | 0.87% |
EPS (Basic) | 94.00 | 30.00 | -65.47 | 63.69 | 127.00 |
EPS (Diluted) | 94.00 | 30.00 | -65.47 | 63.69 | 127.00 |
EPS Growth | 213.33% | - | - | -49.85% | - |
Free Cash Flow | 2,591 | 875.3 | -9,122 | -19,497 | 701.81 |
Free Cash Flow Per Share | 147.32 | 49.41 | -520.75 | -1113.08 | 40.20 |
Dividend Per Share | - | - | 150.000 | 150.000 | - |
Gross Margin | 32.81% | 34.95% | 31.59% | 34.58% | 36.92% |
Operating Margin | 2.21% | 4.49% | 1.39% | 4.43% | 2.80% |
Profit Margin | 1.16% | 0.36% | -0.81% | 0.85% | 1.89% |
Free Cash Flow Margin | 1.81% | 0.59% | -6.45% | -14.78% | 0.60% |
EBITDA | 9,429 | 13,117 | 7,833 | 10,388 | 8,102 |
EBITDA Margin | 6.59% | 8.78% | 5.54% | 7.88% | 6.92% |
D&A For EBITDA | 6,267 | 6,405 | 5,871 | 4,541 | 4,818 |
EBIT | 3,162 | 6,712 | 1,962 | 5,847 | 3,284 |
EBIT Margin | 2.21% | 4.49% | 1.39% | 4.43% | 2.80% |
Effective Tax Rate | 51.24% | 45.16% | - | 49.67% | 56.63% |
Advertising Expenses | 1,554 | 1,696 | 3,127 | 3,256 | 3,598 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.